Literature DB >> 9284941

Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours.

N Matas1, P Thygesen, M Stacey, A Risch, E Sim.   

Abstract

Arylamine N-acetyltransferases (NATs) are encoded at two loci on 8p22, a region subject to deletions in bladder tumours. The two functional genes (AAC1 and AAC2 alias NAT1 and NAT2) without introns in the coding region, encode enzymes which metabolise carcinogens, including bladder carcinogens. They are both multi-allelic and certain alleles have been implicated as susceptibility factors in bladder cancer. There is a third N-acetyltransferase gene, a pseudogene, AACP alias NATP, which we show is also located on chromosome 8 at the p22 region. We have mapped a series of YAC clones (ICI and CEPH) containing the NAT genes and the markers D8S21, an RFLP marker, and D8S261, a microsatellite marker. We show that D8S21 is a portion of the coding region of AAC2. The order of genes in this region, covering some 2 Mb, is TEL-D8S261-AAC1-AACP-AAC2 (D8S21)-CEN. The restriction map also illustrates that there are likely to be other expressed genes in the region through the identification of CpG islands.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284941     DOI: 10.1159/000134601

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  15 in total

1.  Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop.

Authors:  F Rodrigues-Lima; C Deloménie; G H Goodfellow; D M Grant; J M Dupret
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

2.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

Review 3.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

4.  Expression of arylamine N-acetyltransferase in human intestine.

Authors:  D Hickman; J Pope; S D Patil; G Fakis; V Smelt; L A Stanley; M Payton; J D Unadkat; E Sim
Journal:  Gut       Date:  1998-03       Impact factor: 23.059

5.  The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors.

Authors:  H Ishii; R Baffa; S I Numata; Y Murakumo; S Rattan; H Inoue; M Mori; V Fidanza; H Alder; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.

Authors:  G H Goodfellow; J M Dupret; D M Grant
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

7.  Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene.

Authors:  Larissa Wakefield; Hilary Long; Nathan Lack; Edith Sim
Journal:  Mamm Genome       Date:  2007-05-09       Impact factor: 2.957

8.  Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer.

Authors:  Li Jiao; Mark A Doll; David W Hein; Melissa L Bondy; Manal M Hassan; James E Hixson; James L Abbruzzese; Donghui Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-11       Impact factor: 4.254

Review 9.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

10.  A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma.

Authors:  S J Hughes; T W Glover; X X Zhu; R Kuick; D Thoraval; M B Orringer; D G Beer; S Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.